COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00399750
Recruitment Status : Completed
First Posted : November 15, 2006
Last Update Posted : October 15, 2009
Information provided by:

Brief Summary:
A randomized, controlled, open-label multicenter trial to assess the safety and efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) + Bevacizumab (TREE1 and TREE2) as first line therapy of advanced metastatic colorectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: oxaliplatin Drug: fluoropyrimidine Drug: bevacizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 373 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Prospective Study Comparing Three Regimens of Oxaliplatin Plus Fluoropyrimidine and Avastin for Evaluation of Safety and Tolerability in First-line Treatment of Patients With Advanced Colorectal Cancer.
Study Start Date : November 2002
Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Primary Outcome Measures :
  1. To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2)

Secondary Outcome Measures :
  1. The overall incidence of grade 3 and grade 4 adverse events during the first 12 weeks of treatment for each of the oxaliplatin-fluoropyrimidine regimens used without bevacizumab (TREE1)
  2. Type, frequency, severity, timing, and relatedness of all adverse events during treatment and for 30 days following discontinuation of treatment for each of the oxaliplatin-fluoropyrimidine regimens when used with or without bevacizumab(TREE1 and TREE2)
  3. Actual treatment administration as characterized by median, mean, and range of doses given; dose modifications, omissions, and delays; and actual and relative dose intensity (TREE1 and TREE2)
  4. Tumor response rate (overall and confirmed) based on application of the Response Evaluation Criteria in Solid Tumors (RECIST) (TREE1 and TREE2)
  5. Time to treatment failure (TTF) (TREE1 and TREE2)
  6. Time to tumor progression (TTP) (TREE1 and TREE2)
  7. Median survival (TREE1 and TREE2)
  9. A randomized, controlled, open-label multicenter trial to assess the safety & efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) +Avastin (TREE1 & TREE2) as first line therapy of advanced metastatic colorectal cancer
  10. Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.


Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Histologically documented adenocarcinoma of the colon, rectum or appendix.
  2. Metastatic/recurrent disease not amenable to potentially curative treatment (e.g., inoperable metastatic disease).
  3. No prior chemotherapy for metastatic/recurrent disease. Prior adjuvant treatment with 5-FU/LV and/or IFL is allowed if it is completed at least 6 months before study registration.
  4. ECOG Performance Status 0- 1.
  5. At least one unidimensionally measurable lesion with a diameter >/= 20 mm using conventional CT or MRI scans or >/= 10 mm using spiral CT scans. If a single lesion is identified as the target lesion, a histological or cytological confirmation of adenocarcinoma is required.
  6. Recovery in full from any previous surgical procedure.
  7. No other serious concomitant disease.
  8. Required baseline laboratory parameters:

    1. Absolute neutrophil count (ANC) >/=1,500/mm3 (standard international [SI] units 109/L);
    2. Platelets >/= 100,000/mm3 (SI units 109/L);
    3. Hemoglobin >/= 8.0 g/dL (SI units mmol/L);
    4. Creatinine </= 1.5 x ULN; Total bilirubin </= 2.0 x ULN;
    5. Serum glutamate-oxalate transferase (SGOT, AST) Serum glutamic pyruvic transaminase (SGPT, ALT) </= 3 x ULN </= 3 x ULN;
    6. Urinalysis - dipstick Protein < +1;
    7. Coagulation PT/PTT (INR) Within Normal Limits for Institution;
    8. Serum pregnancy test for females of childbearing potential: Negative within 7 calendar days of randomization to study


The presence of any of the following will exclude a subject from study enrollment:

  1. Prior treatment with oxaliplatin or bevacizumab.
  2. Any uncontrolled infection.
  3. History of myocardial infarction within the previous 6 months or current clinical evidence of congestive heart failure, non-stable coronary artery disease, clinically significant hypertension (blood pressure of >160/110 mmHg on medication), or symptomatic peripheral vascular disease.
  4. History of any other cancer (except non melanoma skin cancer or carcinoma in-situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 5 years.
  5. Central nervous system metastases.
  6. Peripheral neuropathy of any cause.
  7. Pregnant or lactating women.
  8. Hypersensitivity to one of the study drugs or ingredients.
  9. Participation in any investigational drug study within 4 weeks preceding enrollment.
  10. Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
  11. Medical or psychiatric disorders that would interfere with informed consent, compliance or make them a poor risk for participation in this trial.
  12. Patients with known DPD deficiency.
  13. Patients with interstitial pneumonia or extensive symptomatic fibrosis of the lungs.
  14. Patients with calculated creatinine clearance of <30 ml/min using Cockroft and Gault formula.
  15. Patients who have received an organ allograft.
  16. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study entry.
  17. Chronic, daily treatment with aspirin (>325 mg/day) or nonsteroidal anti-inflammatory medications (intermittent or "p.r.n." use for pain is permitted).
  18. Evidence of a bleeding diathesis or coagulopathy.
  19. Subjects found to have proteinuria at baseline - If patients are found to have >/= 1+ proteinuria at baseline screening they should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate <2g of protein/24 hr to allow participation in the study.
  20. Patients on chronic therapeutic Warfarin therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00399750

Layout table for location information
United States, New Jersey
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Layout table for investigator information
Study Director: Yasir Nagarwala, M.D. Sanofi
Layout table for additonal information Identifier: NCT00399750    
Other Study ID Numbers: L_8851
First Posted: November 15, 2006    Key Record Dates
Last Update Posted: October 15, 2009
Last Verified: October 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors